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Summary Aims: To evaluate the efficacy and safety of docetaxel–cisplatin in patients
with metastatic or locally advanced non-small cell lung cancer (NSCLC). Methods:
Chemotherapy-na.ıve patients with histologically confirmed TNM stage III or IV NSCLC
were recruited from 12 Asian trial centers. Patients received docetaxel (75mg/m2)
and cisplatin (75mg/m2) every 3 weeks for 6 cycles. Results: 130 of 146 patients were
evaluable for efficacy (60% stage IV). Three complete and 58 partial responses were
observed (overall response rate: 46.9%; 95% CI: 38.3–55.5%). Median time to
progression was 6.9 months and median survival was 14.0 months; 1-year survival
was 59.5%. Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 69.2%,
6.2% and 18.5% of patients, respectively. Grade 3/4 vomiting was observed in 13.7%
and grade 3/4 neurosensory effects were observed in 2.7% of patients. There was one
case of treatment-related death due to sepsis. Conclusion: Docetaxel–cisplatin is an
effective and well-tolerated treatment in Asian patients with NSCLC.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
Lung cancer is a leading cause of cancer deaths in
most parts of the world. Non-small cell lung cancer
(NSCLC) accounts for about 80% of all primary lung
cancers.1 On average, 60% of patients present with
advanced stage IIIB and IV disease.1 The traditional
treatment for NSCLC includes symptomatic relief,
best supportive care, and radiotherapy. In the
recent decade, chemotherapy has also become
the standard therapy for advanced non-small cell
lung cancer.
Platinum-based chemotherapy regimens have
significantly improved tumor response rates, but
increases in survival have been minimal.2,3 New
and novel families of chemotherapeutic agents
that have been developed recently are more
effective in treating NSCLC.4 Docetaxel is a
semisynthetic analog of paclitaxel and inhibits
depolymerization of tubulin.5,6 In vitro and clinical
studies have demonstrated encouraging activity
for docetaxel in NSCLC.5,6 The activity of docetaxel
as a single agent against NSCLC has been estab-
lished in several clinical trials in chemotherapy-
na.ıve patients.7–9 Tumor response rates ranged
from 19% to 38%. In a multicenter phase III trial
of docetaxel plus best supportive care (BSC)
versus BSC alone in 207 patients with advanced
NSCLC, the overall survival and quality of life
were significantly better in docetaxel than in
BSC arm.9 Docetaxel has also demonstrated
significant clinical benefit in NSCLC patients pre-
viously treated with platinum-based chemother-
apy.10–15
In vitro data suggest additive activity for
docetaxel and cisplatin when given in combina-
tion.16 In four recent phase II studies, advanced
NSCLC has been successfully treated with the
combination.17–20 Response rates ranged from
32% to 45%, with a median overall survival range
of 8–12 months. The majority of toxicities were
mild and tolerable. Neutropenia was commonly
dose-limiting and occurred in at least 50% of the
patients.17,21
Although the trials discussed demonstrate en-
couraging results for a docetaxel–cisplatin combi-
nation,17–20,22 studies in non-Caucasian patient
populations are lacking. There is wide international
variation in lung cancer incidence, with Europe and
North America having higher rates than Asia.23 This
variation suggests studies in unique populations are
necessary to improve our knowledge of the disease
and its treatment. Thus, we have conducted a non-
blinded multicenter Asian phase II study for
docetaxel–cisplatin as first-line treatment of ad-
vanced NSCLC.
Patients and methods
Eligibility
This study was a multicenter trial enrolling patients
from different Asian countries. Recruited patients
were aged between 18 and 70 years, with a World
Health Organization (WHO) performance status
p1, and life expectancy X12 weeks. They were
required to have TNM stage III or IV24 or recurrent,
histologically or cytologically proven inoperable
NSCLC with at least one bidimensionally measur-
able lesion. Measurable lesions included superficial
lymph nodes or skin nodules measured directly
(X20 10mm) or by ultrasound (X10 10mm),
pulmonary nodules on chest radiograph (X10
10mm) or lesions on computed tomography or
magnetic resonance imaging (X10 10mm). Bone
metastases, pleural effusion, ascites, and pericar-
dial effusion were not considered measurable
lesions. Previous radiotherapy was permitted if
completed at least 4 weeks prior to chemotherapy,
if measurable disease was completely outside the
radiation portal, and if less than 20% of the marrow
was irradiated. Laboratory values for eligible
patients included neutrophils X2.0 109/l, plate-
lets X100 109/l, hemoglobin X10 g/dl, total
bilirubin o the upper limit of normal (ULN),
aspartate transaminase (AST) and alanine transami-
nase (ALT) o2.5ULN, alkaline phosphatase (ALP)
o5ULN, and serum creatinine o140mmol/l (or
creatinine clearance X60ml/min).
Exclusion criteria included previous administra-
tion of chemotherapy for any malignancy, preg-
nancy, lactating and breastfeeding, presence of
brain or leptomeningeal metastases or other
malignancies. Other exclusion criteria included
symptomatic peripheral neuropathy (Xgrade 1)
by National Cancer Institute (NCI) Common Toxicity
Criteria (CTC), concomitant serious medical condi-
tions (including congestive heart failure or unstable
angina, significant neurologic or psychiatric disor-
ders, active uncontrolled infections), and contra-
indications for the use of corticosteroids. Written
informed consent was obtained from all patients
and the institutional ethics committees approved
the study protocol.
Baseline tests
Baseline hematologic and biochemical profiles,
electrocardiogram, chest radiography, and con-
trast-computed tomography (CT) of the thorax
were performed for all patients prior to study
entry. Imaging of other regions and radionuclide
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bone scan were only performed when clinically
indicated. Investigations were completed within 3
weeks prior to the commencement of chemo-
therapy.
Chemotherapy regimen
The regimen consisted of docetaxel (Taxoteres,
Aventis Pharma) at a dosage of 75mg/m2 in 250ml
5% dextrose administered intravenously over 1 h.
This was followed by intravenous administration of
cisplatin 75mg/m2 in 250ml normal saline over
30–60min on day 1. Dexamethasone (8mg PO)
premedication was given 13, 3, and 1 h before
docetaxel infusions and 12, 24, and 36 h after the
infusion.10,14,20 Ondansetron (8mg IV) was started
1 h prior to docetaxel infusion and continued for 2
more doses every 8 h. The hydration schedule
included 1-l normal saline with 20mmol potassium
chloride and 16mmol magnesium sulfate given over
2 h before docetaxel infusion and 1.5 l 0.45% saline/
2.5% dextrose over 12 h after cisplatin infusion on
day 1. Mannitol (180ml of 20%) was given over 2.5 h
immediately before and after cisplatin infusion on
day 1. Slight variation in the hydration schedule
to allow outpatient administration of the treat-
ment was permitted. Chemotherapy cycles were
repeated every 3 weeks, unless otherwise contra-
indicated, for a total of 6 cycles. More than 6 cycles
of chemotherapy were considered for patients with
complete response.
Evaluation of toxicity and response
The primary objective of the study was to evaluate
response rate of docetaxel 75mg/m2 in combina-
tion with cisplatin 75mg/m2 for 6 cycles in
metastatic or locally advanced NSCLC. The second-
ary objective was to further determine the safety
profile of this combination.
All patients were evaluated once weekly for
treatment-associated toxicities (NCI common toxi-
city [version 1] grading) with hematologic and
biochemical screening tests (electrolytes, liver
and renal function tests) performed. Docetaxel
dose was reduced by 20% in the presence of
prolonged neutropenic fever (neutrophil count
o0.5 109/l for more than 7 days and/or with
temperature 4 381C lasting more than 3 days), or
platelet count o25 109/l. A neutrophil count
o1.5 109/l on day 21 delayed the next cycle of
chemotherapy, and patients were withdrawn from
the study if there was no recovery after 2 weeks.
Further significant toxicities (grade 3 or 4) that
resulted in a 20% dose reduction for docetaxel
included diarrhea, ototoxicity, cutaneous reac-
tions, and elevation of alanine transaminase
(ALT), asparate transaminase (AST), or alkaline
phosphatase (ALP) between 2.5 and 5 times the
ULN. A maximum 2-week postponement was al-
lowed for the next treatment cycle when there was
elevation of AST, ALT, or ALP 45ULN. The
cisplatin dose was reduced by 20% for grade 2
neuropathy and by 50% for nephropathy (creatinine
clearance 40–59ml/min). Patients were also with-
drawn if they exhibited severe (grades 3 and 4)
neuropathy or nephropathy (creatinine clearance
o40ml/min).
The baseline investigations for tumor bulk assess-
ment including chest radiography, computed tomo-
graphy scans, ultrasound scans, or bone scans were
repeated after the third and sixth cycles of
chemotherapy. Evaluation of tumor response was
based on the WHO criteria after 3 and 6 cycles of
treatment.25 Complete response (CR) was defined
as the disappearance of all known malignant
disease. Partial response (PR) was defined as a
decrease of at least 50% in the sum total perpendi-
cular diameters of the largest measurable lesions.
Stable disease or no change (NC) was a o50%
decrease or o25% increase in lesion size, whereas
progressive disease (PD) was a 425% increase.
Confirmation of objective response was included at
least 4 weeks after the initial documentation.
Patients with response to treatment or stable
disease continued to receive a total of 6 cycles of
chemotherapy, unless there was significant toxicity
as described previously. Patients with disease
progression were withdrawn from the study.
Patients were followed for 1 month after comple-
tion of chemotherapy and subsequently every 3
months to documented time to progression (TTP),
ongoing toxicities, and duration of survival.
All patients were evaluated for toxicity as soon as
they entered the study. Patients were required to
have a minimum of 3 treatment cycles with at least
one follow-up assessment to be evaluable for
response, excepting patients classified as having
‘‘early progression’’ (o6 weeks after entry into the
study). TTP was dated from the initial treatment to
progression or last contact, or start of further
therapy (both radiotherapy and rescue chemother-
apy). The duration of survival was the time lapse
between start of treatment and death.
Statistics
The sample size for the study was based on single
stage Fleming design in which a response rate of
20% would not be of further interest and 30% would
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be relevant for further investigations. With a type I
error of 5% and power of 80%, 109 evaluable
patients would be required. Assuming 10% non-
evaluable patients, at least 122 patients should be
included in this trial. TTP and survival times were
calculated using the Kaplan–Meier method. The
statistical package SAS version 8.0 was employed
for all the statistical tests. For continuous data,
summary statistics included frequency (n), median
(if n ¼ 3), minimum and maximum values. If
relevant, the mean and the standard deviation
were added. The 95% confidence interval was
provided for the best overall response.
Results
Demographic data
The patient enrollment of this phase II study
commenced in August 1998 and ended in October
1999. There was a total of 146 patients from 12
participating centers, which were located in Main-
land China (n ¼ 31), Taiwan (n ¼ 21), Singapore
(n ¼ 32), Indonesia (n ¼ 11), Malaysia (n ¼ 10),
Hong Kong (n ¼ 31), and the Philippines (n ¼ 10).
A total of 130 of 146 recruited patients were
evaluable for efficacy (Table 1). Five patients were
ineligible due to poor performance status, grade 4
neutropenia, grade 2 or 3 neuromotor or neurosen-
sory deficits, and radiotherapy less than 4 weeks
before the start of chemotherapy. Ten eligible
patients were not evaluable for efficacy due to a
lack of data on tumor bulk assessment. Another
patient could not be evaluated due to grade 3
hepatic toxicity after one treatment cycle. All
146 patients were evaluable for toxicity. The
majority (71%) were male with a good performance
status (WHO grade 0, 33.6%; grade 1, 65.7%).
The mean7SD (range) age of the patients was
55.979.7 (25–70) years. The majority of the
tumors were histologically diagnosed as adenocar-
cinoma (64%), poorly differentiated (32%), and
some 60% were TNM stage IV. The specific anti-
tumor therapies received prior to the trial regimen
included radiotherapy (n ¼ 8) and surgery (n ¼ 11).
Dose intensity
A median of 6 chemotherapy cycles was given.
Three patients received 7 cycles and 1 patient
received 8 cycles of chemotherapy due to good
clinical response without major toxicity. Reasons
for early chemotherapy termination included dis-
ease progression before administration of cycle 6
(n ¼ 31), adverse effects (n ¼ 7), consent with-
drawal (n ¼ 6), death (n ¼ 3), deviation from
protocol (n ¼ 1), and others (n ¼ 5). The latter
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Table 1 Demographic data for the study population; 145 patients with metastatic or locally advanced (stages III
and IV), and 1 patient with stage IB NSCLC.
Parameters Number (%)
Age (mean7SD, range (years)) 55.979.7, 2570
Gender M:F 103:43
Performance state
WHO 0 49 (33.6%)
WHO 1 96 (65.7%)
WHO 2 1 (0.7%)
Cell type
Adenocarcinoma 94 (64%)
Squamous 38 (26%)
Large cell 4 (3%)
Other 10 (7%)
Staging (TNM) at first diagnosis
IB 1 (0.7%)
III 2 (1.4%)
IIIA 7 (4.8%)
IIIB 48 (32.9%)
IV 88 (60.2%)
Docetaxel and Cisplatin in treatment of non-small cell cancer 799
group included coma with unknown cause (n ¼ 1),
worsening performance status (n ¼ 1), pneu-
mothorax (n ¼ 1), and refusal of follow-up (n ¼ 1).
Dose reduction for docetaxel occurred in 13
patients due to hematological (n ¼ 10) and non-
hematologic toxicities (n ¼ 3). The cisplatin dose
was reduced to 80% in 4 patients and 50% in 1
patient because of non-hematological toxicities.
One patient had cisplatin omitted in 1 cycle
because of renal impairment. Chemotherapy was
delayed for more than 7 days in 21 (16%) patients.
Of these, 9 patient delays were possibly or probably
related to treatment. Causes for the 9 delays
included neutropenia (n ¼ 2), infection (n ¼ 2),
fever in the absence of infection (n ¼ 1), and
asthenia/fatigue (n ¼ 3). Two patients required
hospitalization for infection (grade 2) and asthe-
nia/fatigue (grade 3).
Tumor response and survival
There were 130 patients eligible for assessment of
tumor response. An objective response (CRþ PR)
was detected in 61 patients (46.9%, 95% CI 38.3–
55.5%), with 3 of these classified as having a CR.
Stable disease was observed in 48 patients (36.9%)
and progressive disease in 21 patients (16.2%). In an
intent-to-treat analysis, the corresponding re-
sponse rates were 43.2% (95% CI 35.1–51.2%)
(CRþ PR), 35.6% (NC), and 15.1% (PD) (Table 2).
In the intent-to-treat population, the median
duration of patient follow-up was 45 weeks. The
median TTP as calculated from the start of
chemotherapy was 6.9 months (95% CI 5.7–7.6
months). The 76 deaths observed were due to
malignant disease (n ¼ 70), severe sepsis (n ¼ 2),
respiratory failure (n ¼ 2), cardiac arrhythmia
(n ¼ 1), and unknown cause of cardiac arrest
(n ¼ 1). One of the deaths due to sepsis occurred
during chemotherapy treatment. Using the Kaplan–
Meier method, median survival was calculated to
be 14.0 months (95% CI 12.3–15.8 months) with a 1-
year survival rate of 59.5%. The TTP and median
survival were similar (P40:05) in patients with
different stage (stage III vs. IV), performance
status (WHO 0 vs. 1–2) and histology (adenocarci-
noma vs others). The median survival was signifi-
cantly longer in female patients as compared with
male patients (12.775.5 vs. 9.875.5 months,
P ¼ 0:003).
Toxicity profile
All 146 patients were eligible for assessment of
chemotherapy-related toxicities. Grade 3 or 4
neutropenia occurred in 69.2%, thrombocytopenia
in 6.2% and anemia in 18.5% of patients, respec-
tively (Table 3). The median times from chemother-
apy infusions to nadir for hemoglobin, neutrophils,
and platelets were 9, 7, and 7 days, respectively.
Febrile neutropenia occurred in 8.2% of patients,
while 4.5% of patients experienced Grade 3 or 4
treatment-related infections. There was one toxic
death (0.7%) during the course of chemotherapy.
Other clinically significant (grade 3 or 4) toxi-
cities included allergy (2.7% of patients), alopecia
(59.5%, grade 2: pronounced hair loss), asthenia
(6.2%), neurosensory changes (2.7%), nausea
(11.6%), vomiting (13.7%), diarrhea (4.1%) and
stomatitis (2.1%) (Table 3). Relatively common but
mild toxicities (grade 1 or 2) included alopecia,
allergy, nausea, vomiting, diarrhea, fever, infec-
tion, asthenia, stomatitis, skin reaction, edema,
neurosensory changes, neuromotor changes, and
nail changes. In particular, peripheral edema
usually developed in later cycles of chemotherapy,
with some patients requiring low-dose frusemide
therapy. No patients had clinically significant
(grade 3 or 4) docetaxel-related pleural or peri-
cardial effusions.
Discussion
The efficacy results (OR 46.9%; 1-year survival
59.5%) of this phase II study clearly demonstrate
that the docetaxel–cisplatin combination is an
effective regimen in the first-line treatment
of locally advanced or metastatic NSCLC. The
high proportion of adenocarcinoma in the study
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Table 2 Tumor response rates among the evaluable and intent-to-treat patients who underwent combined
treatment with docetaxel and cisplatin.
Patient population CR, n (%) PR, n (%) NC, n (%) PD, n (%) NE, n (%) Total n
Evaluable 3 (2.3) 58 (44.6) 48 (36.9) 21 (16.2) 0 (0) 130
Intent-to treat 3 (2.1) 60 (41.1) 52 (35.6) 22 (15.1) 9 (6.1) 146
CR, complete response; PR, partial response; NC, stable disease; PD, progressive disease; NE, not evaluable.
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population is in accordance with the rising inci-
dence of lung adenocarcinoma in Asian countries,
particularly in the female population.26–30 The
objective tumor response rate in this cohort was
43.2%, with stable disease observed in 35.6% of
patients.
Despite the relatively short median TTP of 6.9
months after commencement of chemotherapy, our
study population had an encouraging median
survival of 14 months. This is clinically significant
when compared with the median survivals of 8 and
5 months observed with mitomycin C–ifosfamide–
cisplatin and best supportive care, respectively,
in a previous comparable study conducted in
Hong Kong.1 The results also compare favorably
with those seen for docetaxel–cisplatin in non-
Asian specific populations.17–20 One-year survival
(59.5%) was superior to that seen in other studies
(33–48%).18–20 In a recent phase III Eastern
Cooperative Oncology Group Trial comparing 4
different chemotherapy arms,31 the subgroup of
304 patients who were treated with docetaxel and
cisplatin had tumor response of 17% and median
survival of 7.4 months. These results were com-
paratively less favorable than those obtained in our
study, possibly due to the inclusion of patients with
brain metastases (13%) and the presence of a higher
proportion of stage IV disease (86%). In addition, a
recent multicenter phase III trial comparing
a reference arm of vinorelbine–cisplatin with
docetaxel–cisplatin or docetaxel–carboplatin in
1220 patients with advanced NSCLC showed sig-
nificant improvement in overall survival with
docetaxel–cisplatin treatment.32 However, the op-
timal regimen for treatment of NSCLC in non-
Caucasian populations could only be evaluated by
conducting phase III trials, in which efficacy and
toxicity are compared to the best available
standard treatment. It should be noted that
patients with brain or leptomeningeal metastases
were excluded from our study since this therapeu-
tic combination has theoretically poor cerebrosp-
inal fluid distribution.
In addition, our results showed that the docetax-
el–cisplatin combination had an acceptable safety
profile in the treatment of patients with NSCLC.
The most common cause for dose reduction or
delay of chemotherapy was hematologic toxicity,
although some 65% of patients were able to receive
the intended 6 cycles of chemotherapy. Severe
(grade 3/4) neutropenia and thrombocytopenia
occurred in 69.2% and 6.2% of patients, respec-
tively. Other common toxicities including periph-
eral edema usually occurred during the later cycles
of chemotherapy (cycle 3 or 4 onwards) and were
reported as mild or moderate. Several recent phase
II trials involving docetaxel–cisplatin (75–100mg/
m2) have also observed neutropenia in more than
50% of patients, with other toxicities being mild
and moderate.17,21 However, neutropenia is a
predictable and manageable side effect that can
be minimized by the use of G-CSF.21
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Table 3 Chemotherapy-related toxicities for patients treated with a combination of docetaxel and cisplatin.
Toxicities % (n)
NCI CTC grades 1 or 2 NCI CTC grade 3 NCI CTC grade 4
Hematologic
Neutropenia 13.7 (20) 19.2 (28) 50 (73)
Thrombocytopenia 33.6 (49) 2.7 (4) 3.4 (5)
Anemia 76.7 (112) 11.6 (17) 6.9 (10)
Non-hematologic
Vomiting 50.7 (74) 12.3 (18) 1.4 (2)
Nausea 65.1 (95) 11.6 (17) 0
Alopecia 85 (124) NA NA
Asthenia 65.1 (95) 6.2 (9) 0
Diarrhea 47.3 (69) 3.4 (5) 0.7 (1)
Infection 11.6 (17) 3.4 (5) 0.7 (1)
Neurosensory 58.2 (85) 2.7 (4) 0
Allergy 24.7 (36) 0.7 (1) 2.1 (3)
Stomatitis 22.6 (33) 1.4 (2) 0.7 (1)
Pain 24.0 (35) 1.4 (2) 0.7 (1)
Skin 20.5 (30) 1.4 (2) 0
Edema 94.5 (138) 1.4 (2) 0
NCI CTC, National Cancer Institute Common Toxicity Criteria; NA, not applicable.
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Conclusion
This phase II study demonstrates first-line doc-
etaxel–cisplatin provides encouraging response
rates and survival outcome in Asian patients with
advanced NSCLC. Although further development of
combination in this population will require rando-
mized phase III trials, our results are comparable to
those seen in Caucasian patients17–20 and provide a
good platform for further studies.
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